Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 May 6;88(9):1417-23.
doi: 10.1038/sj.bjc.6600922.

Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray

Affiliations

Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray

Y Hedberg et al. Br J Cancer. .

Abstract

Aberrations in the G1/S transition of the cell cycle have been observed in many malignancies and seem to be critical in the transformation process. Few studies have delineated the presence of G1/S regulatory defects and their clinical relevance in renal cell carcinoma (RCC). Therefore, we have examined the protein contents of cyclin D1, D3, E, and p27 in 218 RCCs, using tissue microarray and immunohistochemistry. The results from a subset of tumours were confirmed by Western blotting and immunohistochemical staining of regular tissue sections. Interestingly, low protein contents of cyclin D1 and p27 were associated with high nuclear grade, large tumour size, and poor prognosis for patients with conventional tumours. We further observed substantial differences in the pattern of G1/S regulatory defects between the different RCC subtypes. The majority of both conventional and papillary cases expressed p27; however, chromophobe tumours generally lacked p27 staining. In addition, conventional RCCs often expressed high cyclin D1 protein levels, while papillary RCCs exhibited high cyclin E. In summary, we have shown that G1/S regulatory defects are present in RCC and are associated with clinico-pathological parameters. The pattern of cell cycle regulatory defects also differed between RCC subtypes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Illustration of cyclin D1, D3, E, and p27 immunohistochemistry staining of RCC using TMA technique. The left column illustrates a low protein expression, and the right column shows tumours with high content of the cell-cycle-regulating proteins.
Figure 2
Figure 2
Illustration of Western blot analysis of cyclin D1, D3, E, and actin in RCC. Actin was used as a loading control. The first lane, marked 9003 N, represents corresponding kidney cortex from patient 9003, whereas the tumour sample was loaded in lane 2. The other six lanes contain tumour samples to illustrate the variation in protein contents between the tumours.
Figure 3
Figure 3
Comparison between TMA-based immunohistochemistry analysis of cyclin D1, D3, E, and p27 (1–4) with (A) Western-blot-based analysis (cyclin D1, D3, and E) or (B) immunohistochemistry of regular sections (p27).
Figure 4
Figure 4
Kaplan–Meier survival curves for patients with conventional RCC: (A) cyclin D1 (low vs high levels); (B) p27 (low vs high levels).
Figure 5
Figure 5
An illustration of the combinations of alterations in cell cycle regulatory proteins in (A) 163 conventional, (B) 27 papillary, and (C) 13 chromophobe RCC. The light grey bars represent tumours having low p27 levels, while the dark grey bars represent tumours with high p27 levels. The presence of low and high cyclin expression are indicated as − and +.

Similar articles

Cited by

References

    1. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjanen K, Kosma VM (1999) Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br J Cancer 80: 2001–2007 - PMC - PubMed
    1. Åkervall JA, Michalides RJ, Mineta H, Balm A, Borg A, Dictor MR, Jin Y, Loftus B, Mertens F, Wennerberg JP (1997) Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 79: 380–389 - PubMed
    1. Bartkova J, Zemanova M, Bartek J (1996) Abundance and subcellular localisation of cyclin D3 in human tumours. Int J Cancer 65: 323–327 - PubMed
    1. Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80: 1943–1949 - PubMed
    1. Demetrick DJ, Matsumoto S, Hannon GJ, Okamoto K, Xiong Y, Zhang H, Beach DH (1995) Chromosomal mapping of the genes for the human cell cycle proteins cyclin C (CCNC), cyclin E (CCNE), p21 (CDKN1) and KAP (CDKN3). Cytogenet Cell Genet 69: 190–192 - PubMed

Publication types

MeSH terms